Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
ConclusionThe trial results will provide evidence on whether the efficacy and safety of dupilumab support its use as a potential novel treatment approach for BP and will provide new insights into the role of type 2 inflammation in BP pathogenesis.Clinical Trial RegistrationClinicalTrials.gov identifier NCT04206553.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Autoimmune Disease | Clinical Trials | Corticosteroid Therapy | Drugs & Pharmacology | Pemphigoid | Skin | Steroid Therapy | Study | Toxicology